Regeneron (Nasdaq: REGN) and Sanofi (Euronext: SAN) have presented new data on the PD-1 inhibitor Libtayo (cemiplimab-rwlc) from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (CSCC), the deadliest non-melanoma skin cancer.
These results demonstrate both longer durability and higher complete response rates than previously reported.
The data make up part of the largest and most mature prospective clinical dataset in patients with metastatic CSCC or locally-advanced CSCC who are not candidates for curative surgery or radiation.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze